MTOR and oral cavity neoplasm: This pathway dependence is also being investigated clinically in multiple trials using direct PI3K and/or mTOR inhibitors in oral cavity, as well as by the use of metformin, which blocks mTOR indirectly, for oral cavity tumors prevention in patients with potential premalignant lesions [154,155].